Nonmelanoma skin cancers (NMSCs) in ruxolitinib-treated patients with myeloproliferative neoplasms behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis. Vigilant skin assessment, counseling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood.2023022345 | DOI Listing |
Publication Analysis
Top Keywords
nonmelanoma skin
8
skin cancers
8
patients myeloproliferative
8
myeloproliferative neoplasms
8
outcomes characteristics
4
characteristics nonmelanoma
4
cancers patients
4
neoplasms ruxolitinib
4
ruxolitinib nonmelanoma
4
cancers nmscs
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!